Skip to main content

Table 3 Percentage of patients that developed adverse effects to TKI

From: Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Unwanted effect Afatinib (n = 40) Erlotinib (n = 26) Gefitinib (n = 33)
  Any Grade Grade 3–4 Any Grade Grade 3–4 Any Grade Grade 3–4
Any unwanted effect 36 (90%) 3 (7.5%) 26 (100%) 4 (15.4%) 26 (78.8%) 1 (3%)
• Rash 23 (57.5%) 1 (2.5%) 13 (50%) 1 (3.8%) 13 (39.4%) 0 (0.0%)
• Diarrhea 14 (35%) 2 (5%) 13 (50%) 2 (7.7%) 18 (54.5%) 0 (0.0%)
• Xerosis 16 (40%) 0 (0.0%) 9 (34.6%) 0 (0.0%) 12 (36.4%) 0 (0.0%)
• Paronychia 11 (27.5%) 0 (0.0%) 4 (15.4%) 0 (0.0%) 4 (12.1%) 0 (0.0%)
• Nausea 3 (7.5%) 0 (0.0%) 7 (26.9%) 0 (0.0%) 7 (21.2%) 0 (0.0%)
• Acne 6 (15%) 0 (0.0%) 6 (23.1%) 0 (0.0%) 1 (3%) 0 (0.0%)
• Fatigue 5 (12.5%) 0 (0.0%) 6 (23.1%) 0 (0.0%) 2 (6.1%) 0 (0.0%)
• Stomatitis 6 (15%) 0 (0.0%) 5 (19.2%) 0 (0.0%) 5 (15.2%) 0 (0.0%)
• Constipation 2 (5%) 0 (0.0%) 4 (15.4%) 0 (0.0%) 3 (9.1%) 0 (0.0%)
• Vomit 2 (5%) 0 (0.0%) 3 (11.5%) 0 (0.0%) 1 (3%) 0 (0.0%)
• Alopecia 1 (2.5%) 0 (0.0%) 0 (0%) 0 (0.0%) 3 (9.1%) 1 (3%)
• Neuropathy 2 (5%) 0 (0.0%) 0 (0%) 0 (0.0%) 3 (9.1%) 0 (0.0%)
• Anorexia 3 (7.5%) 0 (0.0%) 0 (0%) 0 (0.0%) 1 (3%) 0 (0.0%)
• Liver toxicity 0 (0%) 0 (0.0%) 1 (3.8%) 0 (0.0%) 0 (0%) 0 (0.0%)
• Anemia 0 (0%) 0 (0.0%) 0 (0%) 0 (0.0%) 1 (3%) 0 (0.0%)
• Arthralgia 1 (2.5%) 0 (0.0%) 0 (0%) 0 (0.0%) 1 (3%) 0 (0.0%)